Država: Avstralija
Jezik: angleščina
Source: APVMA (Australian Pesticides and Veterinary Medicines Authority)
BUDESONIDE
DERMCARE-VET PTY. LTD.
TOPICAL CREAM, OINTMENT, PASTE, GEL, LOTION
BUDESONIDE Active 0.25 g/L
100 mL
VM - Veterinary Medicine
ENDOCRINE SYSTEM
Poison schedule: 4; Withholding period: ; Host/pest details: DOG: [CANINE ATOPIC DERMATITIS, CONTACT ALLERGY, PRURITIC CONDITIONS]
Registered
2021-07-01
DERMCARE BARAZONE 0.25 g/L BUDESONIDE LEAVE-ON CONDITIONER 82108/136828 Product Name: APVMA Approval No: Label Name: DERMCARE BARAZONE 0.25 g/L BUDESONIDE LEAVE-ON CONDITIONER Signal Headings: PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY READ SAFETY DIRECTIONS BEFORE OPENING OR USING Constituent Statements: 0.25 g/L BUDESONIDE Claims: For use only by or under supervision of a veterinarian. For the symptomatic treatment of Canine Atopic Dermatitis, contact allergy and other pruritic conditions of the dog. Net Contents: 100 mL Directions for Use: Restraints: Contraindications: NOT TO BE USED in any situation where corticosteroids are contraindicated. Precautions: Use with caution. Dermcare Barazone Budesonide Leave-On Conditioner contains an anti-inflammatory corticosteroid (budesonide). Side effects are consistent with the use of corticosteroids. The use of Barazone in conjunction with other topical glucocorticoids or systemic glucocorticoids has not been established. Concurrent use of these medications may increase the risk of side effects associated with corticosteroids. Barazone may affect the results of an Intradermal Skin Test or biopsy. The use of this product has not been tested in stud dogs and pregnant or lactating bitches. Its use in these animals should be based on a risk-benefit analysis by the prescribing veterinarian. RLP APPROVED Long term application of this product should be done so with caution. Monitoring of side effects associated with the use of topical glucocorticoids should be carried out by a registered veterinarian. Potential adverse reactions of topical glucocorticoids include coat thinning, slow regrowth of hair, atrophy of the skin, and erythema. In the Target Animal Safety Studies conducted, there were no serious adverse events reported. No reports of clinical changes to the coat or skin occurred when up to 3x maximum dose rate was applied for 6 consecutive weeks. Routine haematology and biochemistry parameters remained within reference ranges afte Preberite celoten dokument